期刊文献+

贝达喹啉中间体3-苄基-6-溴-2-甲氧基喹啉的合成工艺优化

Optimization of synthetic process of 3-benzyl-6-bromo-2-methoxyquinoline
下载PDF
导出
摘要 贝达喹啉是本世纪初开发上市的新型二芳基喹啉类药物,而3-苄基-6-溴-2-甲氧基喹啉是合成贝达喹啉的重要中间体。本文针对此中间体合成时间长,收率低的问题,通过探讨不同的反应时间、温度、溶剂等因素对其影响,寻找到较优的反应条件,提高了反应收率,缩短了反应时间,便于工业化生产。 Beidaquiline is a novel diaryl quinoline drug developed and marketed at the beginning of this century,and 3-benzyl-6-bromo-2-methoxyquinoline is an important intermediate for the synthesis of bedaquiline.This article aimed at the problem of long synthesis time and low yield of this intermediate.Through the discussion of different reaction time,temperature,solvent and other factors,it found better reaction conditions,improved the reaction yield and shortened the reaction time.This condition facilitated industrial production.
作者 张焕 丁娇 曾祥聪 李丽 潘晓涵 祝宏 ZHANG Huan;DING Jiao;ZENG Xiang-cong;LI Li;PAN Xiao-han;ZHU Hong(School of chemical engineering and pharmacy,Wuhan Institute of Technology,Wuhan,430073,China)
出处 《化学研究与应用》 CAS CSCD 北大核心 2019年第1期123-127,共5页 Chemical Research and Application
基金 武汉工程大学研究生教育创新基金项目(CX2017147)资助
关键词 贝达喹啉中间体 3-苄基-6-溴-2-甲氧基喹啉 工艺优化 beidaquiline intermediate 3-benzyl-6-bromo-2-methoxy quinoline process optimization
  • 相关文献

参考文献6

二级参考文献81

  • 1Mullard A. 2012 FDA drug approvals [J]. Nat Rev Drug Discov, 2013, 12(2): 87-90.
  • 2Davis P B, Yasothan U, Kirkpatrick P. Ivacaftor [J]. Nat Rev Drug Discov, 2012, 11 (5): 349-350.
  • 3Corbyn Z. Promising new era dawns for cystic fibrosis treatment [J]. Lancet, 2012, 379(9825): 1475-1476.
  • 4de Lartigue J. Tofacitinib for the treatment of moderate to severe rheumatoid arthritis [J]. Drugs Today (Barc), 2012, 48(8): 533-543.
  • 5Zerbini C A, Lomonte A B. Tofacitinib for the treatment of rheumatoid arthritis [J]. Expert Rev Clin lmmunol, 2012, 8(4): 319-31.
  • 6Fleischmann R, Kremer J, Cush J, et al. Placebo- controlled trial of tofacitinib monotherapy in rheumatoid arthritis I J]. NEnglJMed, 2012, 367(6): 495-507.
  • 7van Vollenhoven R F, Flelschrnarm R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis [J]. NEnglJMed, 2012, 367(6): 508-519.
  • 8Pal S K, Stein C A, Sartor O. Enzalutamide for the treatment of prostate cancer [J]. Expert Opin Pharmacother, 2013, 14(5): 679-685.
  • 9Scher H I, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy [J]. N EnglJMed, 2012, 367(13): 1187-1197.
  • 10Keating G M. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer [J]. Drugs, 2012, 72(3): 353-360.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部